Literature DB >> 7494404

The hepatic glycogen storage diseases--problems beyond childhood.

P J Lee1, J V Leonard.   

Abstract

The introduction of continuous nocturnal enteral glucose feeds and uncooked cornstarch has improved the prognosis for patients with the hepatic glycogen storage diseases. An increasing number of patients are surviving into adulthood in better health, but still at some medical cost. In this review we examine bone mineralization, renal function, hepatic tumours, and vascular endothelial function in GSD I and cardiac function in GSD III. All females over the age of 5 years with GSD I, III, VI and IX had morphologically polycystic ovaries. Thirteen adult GSD I patients have been studied, and been found to have poor bone mineralization and marked renal glomerular and tubular dysfunction. More than half of these patients also had focal hepatic lesions on sonography and yet vascular endothelial function was preserved in the face of hyperlipidaemia. In 12 GSD III patients, one had a focal hepatic lesion and 6 had pronounced left ventricular hypertrophy, although cardiorespiratory function was normal. These data emphasize the multisystem nature of these disorders and highlight the need for careful longterm follow-up.

Entities:  

Mesh:

Year:  1995        PMID: 7494404     DOI: 10.1007/bf00710057

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  36 in total

1.  Glycogen disease of the liver (von Gierke's disease) with hepatomata; case report with metabolic studies.

Authors:  H H MASON; D H ANDERSEN
Journal:  Pediatrics       Date:  1955-12       Impact factor: 7.124

2.  [Long-term course of hepatic glycogenosis. A retrospective study of 76 cases].

Authors:  L de Parscau; P Guibaud; P Labrune; M Odièvre
Journal:  Arch Fr Pediatr       Date:  1988-11

3.  Glomerular and tubular function in glycogen storage disease.

Authors:  P J Lee; R N Dalton; V Shah; P C Hindmarsh; J V Leonard
Journal:  Pediatr Nephrol       Date:  1995-12       Impact factor: 3.714

4.  [Evaluation of the mineral content of peripheral bones (radius) by photon-absorption technique in normals as well as in patients with various types of bone diseases (author's transl)].

Authors:  H Runge; F Fengler; J Franke; W Koall
Journal:  Radiologe       Date:  1980-10       Impact factor: 0.635

5.  Hyperlipidemia and fatty acid composition in patients treated for type IA glycogen storage disease.

Authors:  H L Greene; L L Swift; H R Knapp
Journal:  J Pediatr       Date:  1991-09       Impact factor: 4.406

Review 6.  Glucose-6-phosphate: a key compound in glycogenosis I and favism leading to hyper- or hypolipidaemia.

Authors:  G Schmitz; H Hohage; K Ullrich
Journal:  Eur J Pediatr       Date:  1993       Impact factor: 3.183

7.  Hyperlipidaemia does not impair vascular endothelial function in glycogen storage disease type 1a.

Authors:  P J Lee; D S Celermajer; J Robinson; S N McCarthy; D J Betteridge; J V Leonard
Journal:  Atherosclerosis       Date:  1994-09-30       Impact factor: 5.162

8.  Hepatocellular carcinoma in type I glycogen storage disease.

Authors:  J Limmer; W E Fleig; D Leupold; R Bittner; H Ditschuneit; H G Beger
Journal:  Hepatology       Date:  1988 May-Jun       Impact factor: 17.425

9.  Regression of hepatic adenomas in type Ia glycogen storage disease with dietary therapy.

Authors:  P Parker; I Burr; A Slonim; F K Ghishan; H Greene
Journal:  Gastroenterology       Date:  1981-09       Impact factor: 22.682

10.  Serum Lp(a) lipoprotein concentrations in insulin dependent diabetic patients with microalbuminuria.

Authors:  H Kapelrud; H J Bangstad; K Dahl-Jørgensen; K Berg; K F Hanssen
Journal:  BMJ       Date:  1991-09-21
View more
  9 in total

Review 1.  Dietary dilemmas in the management of glycogen storage disease type I.

Authors:  Kaustuv Bhattacharya
Journal:  J Inherit Metab Dis       Date:  2011-04-14       Impact factor: 4.982

2.  Plasma creatine kinase and cardiomyopathy in glycogen storage disease type III.

Authors:  P Lee; M Burch; J V Leonard
Journal:  J Inherit Metab Dis       Date:  1995       Impact factor: 4.982

3.  Glycogen storage disease type Ia: frequency and clinical course in Turkish children.

Authors:  I N Saltik; H Ozen; G Ciliv; N Koçak; A Yüce; F Gürakan; G Dinler
Journal:  Indian J Pediatr       Date:  2000-07       Impact factor: 1.967

4.  Bone mineral density and markers of bone turnover in patients with glycogen storage disease types I, III and IX.

Authors:  J Cabrera-Abreu; N J Crabtree; E Elias; W Fraser; R Cramb; S Alger
Journal:  J Inherit Metab Dis       Date:  2004       Impact factor: 4.982

5.  A novel starch for the treatment of glycogen storage diseases.

Authors:  K Bhattacharya; R C Orton; X Qi; H Mundy; D W Morley; M P Champion; S Eaton; R F Tester; P J Lee
Journal:  J Inherit Metab Dis       Date:  2007-05-19       Impact factor: 4.982

6.  Renal function in glycogen storage disease type I, natural course, and renopreservative effects of ACE inhibition.

Authors:  Daniëlle H J Martens; Jan Peter Rake; Gerjan Navis; Vaclav Fidler; Catharina M L van Dael; G Peter A Smit
Journal:  Clin J Am Soc Nephrol       Date:  2009-10-01       Impact factor: 8.237

Review 7.  Investigation and management of the hepatic glycogen storage diseases.

Authors:  Kaustuv Bhattacharya
Journal:  Transl Pediatr       Date:  2015-07

8.  Echocardiographic manifestations of Glycogen Storage Disease III: increase in wall thickness and left ventricular mass over time.

Authors:  Shawyntee M Vertilus; Stephanie L Austin; Kimberly S Foster; Keri E Boyette; Deeksha S Bali; Jennifer S Li; Priya S Kishnani; Stephanie Burns Wechsler
Journal:  Genet Med       Date:  2010-07       Impact factor: 8.822

9.  A pilot longitudinal study of the use of waxy maize heat modified starch in the treatment of adults with glycogen storage disease type I: a randomized double-blind cross-over study.

Authors:  Kaustuv Bhattacharya; Helen Mundy; Maggie F Lilburn; Michael P Champion; David W Morley; François Maillot
Journal:  Orphanet J Rare Dis       Date:  2015-02-15       Impact factor: 4.123

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.